T
Teriparatide [Teriparatide-Teva]
Availability of ACE Drug Guidance
Yes
Biologics Drug Information Overview
No
Subsidy Information and Financing Scheme
No
Active ingredient: Teriparatide
General information
Subsidy Information and Financing Scheme
Not Applicable
Drug Guidance for Subsidy
04/06/2025 Teriparatide biosimilar for treating osteoporosis
The Ministry of Health’s Drug Advisory Committee has recommended teriparatide biosimilar (Sondelbay) 600 mcg/2.4 mL injection for treatment of patients with severe established osteoporosis (T-score ≤ -3.0) with a history of ≥ 2 vertebral fractures or ≥ 2 fragility fractures. The maximum lifetime duration of teriparatide treatment should be limited to 24 months. The decision was based on the acceptable pricing proposal from the company.
Funding status
[R] Teriparatide biosimilar (Sondelbay) 600 mcg/2.4 mL injection is recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indication from 1 August 2025.
[NR] MAF assistance does not apply to other brand(s), formulation(s) or strengths(s) of teriparatide for treating osteoporosis.
Registered Product(s) Information
Clinical and product info
Clinical info | Product Info |
|---|---|
Information under the Indication, Dosage and Contraindication sections are extracted from the relevant Package Insert/Patient Information Leaflet of the product available on HSA Infosearch. For more information, please refer to the product's Package Insert/ Patient Information Leaflet available on HSA Infosearch. The information provided is for informational purposes only, and is not exhaustive. The information provided is not a substitute for professional medical advice. Please consult a qualified healthcare provider for any medical advice. | Information available here are product details as registered with the HSA. As this website is updated monthly, please refer to HSA Infosearch for the most updated product information. |
Subcutaneous
* Clinical information is available for this product.